Menu
Search
|

Menu

Close
X

Zafgen Inc ZFGN.OQ (NASDAQ Stock Exchange Global Select Market)

10.92 USD
-- (--)
As of Jul 19
chart
Previous Close 10.92
Open --
Volume --
3m Avg Volume 89,516
Today’s High --
Today’s Low --
52 Week High 11.21
52 Week Low 3.21
Shares Outstanding (mil) 27.48
Market Capitalization (mil) 94.27
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.579
FY17
-1.897
FY16
-2.121
FY15
-2.767
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
0.95
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
2.07
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-42.22
14.61
Return on Equity (TTM)
vs sector
-42.56
16.34

EXECUTIVE LEADERSHIP

Peter Barrett
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Thomas Hughes
President, Chief Scientific Officer, Director, Since 2017
Salary: $450,000.00
Bonus: --
Jeffrey Hatfield
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Patricia Allen
Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Dennis Kim
Chief Medical Officer, Since 2011
Salary: $367,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

175 Portland St Fl 4
BOSTON   MA   02114-1713

Phone: +1617.6224003

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

SPONSORED STORIES